J.P. Morgan Life Sciences Private Capital Hires Joseph Siletto to Target Investments in Healthcare Transformation
J.P. Morgan Private Capital has announced the appointment of Joseph Siletto as Co-Managing Partner in their Life Sciences Private Capital division. Siletto, previously with Vivo Capital, will work alongside Anya Schiess and Gaurav Gupta, focusing on investments in healthcare companies from Series B to pre-IPO stages. The team will target sectors like biotechnology, medical devices, health tech, and diagnostics. With over 25 years of experience, Siletto aims to leverage J.P. Morgan's resources to identify innovative healthcare opportunities that improve disease treatment and patient outcomes.
- Joseph Siletto brings over 25 years of experience in private healthcare investments.
- The expanded team will focus on transformative healthcare investments, potentially enhancing disease treatment and patient outcomes.
- J.P. Morgan's broadened platform aims to leverage biotechnology and AI advances, potentially giving them a significant sourcing advantage.
- Potential challenges in integrating new leadership dynamics could impact investment strategies.
- Market risks associated with investing in cutting-edge technology and early-stage companies may increase volatility.
Mr. Siletto joins from Vivo Capital as Co-Managing Partner
"I'm delighted to join the globally esteemed team at J.P. Morgan Life Sciences Private Capital," said Joseph Siletto, Managing Partner, J.P. Morgan Life Sciences Private Capital. "As part of a world-class investment team, I'm looking forward to leveraging J.P. Morgan's existing presence in the healthcare sector that we believe will give us a significant sourcing advantage as we seek to identify innovative and transformative healthcare companies."
Based in
The expanded platform will look to finance opportunities that aim to enhance disease treatment and patient outcomes while reducing costs through several key initiatives, including but not limited to: supporting innovative treatment methods, utilizing cutting-edge technology, applying increased computing power with artificial intelligence to develop more impactful treatments, improving diagnostic tools for earlier disease detection and prevention, and delivering healthcare solutions to patients in a more cost effective way.
"As advances in biotechnology and artificial intelligence continue to transform the healthcare industry, our expanded team should allow us to take advantage of this transition, and remain a preferred partner for companies looking to implement innovative ways to treat, identify and prevent disease," said Anya Schiess, Managing Partner, J.P. Morgan Life Sciences Private Capital.
Biography
Joseph Siletto is Co-Managing Partner of Life Sciences Private Capital ("LSPC") within J.P. Morgan Private Capital, a division of J.P. Morgan Global Alternatives in J.P. Morgan Asset Management. Joseph joined from Vivo Capital in 2024. While at Vivo, Joseph focused on sourcing investments, executing transactions and serving on the board of directors for growth and private equity companies. Over his time with the firm, he sourced and served on the board of over 10 companies. In addition to his investment and board responsibilities, Joseph also took an active operations role within several portfolio companies. Prior to his time at Vivo, Joseph created the business plan and was the co-founder for Scion Medical Technologies, a company which completed a half dozen acquisitions to build a global, commercial medical device portfolio focused on interventional oncology. Scion was ultimately sold to NYSE-listed Varian Medial and is now part of Siemens. Prior to his time as an entrepreneur and investor, Joseph was an investment banker for Cowen & Company and Banc of America Securities focused on healthcare M&A and capital raising. Joseph has a Bachelor of Arts from Duke University and an MBA from the Haas School of Business at the University of
About J.P. Morgan Private Capital
J.P. Morgan Private Capital provides customized financing solutions for private companies across the capital structure with a focus on venture and growth investing. The platform's solutions span the consumer, technology, and life sciences sectors.
J.P. Morgan Private Capital is part of J.P. Morgan Global Alternatives, the alternative investment arm of J.P. Morgan Asset Management. With over 60 years of experience in managing alternative investments,
About J.P. Morgan Asset Management
J.P. Morgan Asset Management, with assets under management of
JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in
J.P. Morgan Life Sciences team members' past investing and operating experience is provided solely in order to illustrate the nature of their professional experience with respect to the types of investments and transactions that JPM intends to pursue and is not indicative of JPM's future results and should not be understood as JPM's "track record" information or be relied upon in connection with any investment or other related decision.
View original content to download multimedia:https://www.prnewswire.com/news-releases/jp-morgan-life-sciences-private-capital-hires-joseph-siletto-to-target-investments-in-healthcare-transformation-302194781.html
SOURCE J.P. Morgan Asset Management
FAQ
Who is the new Co-Managing Partner at J.P. Morgan Life Sciences Private Capital?
What is the focus of J.P. Morgan Life Sciences Private Capital under Joseph Siletto?
What experience does Joseph Siletto bring to J.P. Morgan Life Sciences Private Capital?